Question 16292 — diseases

Summary

Mr. Jean-Pierre Door draws the attention of the Secretary of State to the Minister of Solidarity and Health to cervical cancer screening technologies reimbursed in France. Cervical cancer is a transmissible cancer which is characterized by a slow progression and the appearance of precancerous lesions that can be identified and cured well in advance. Responsible each year in France for the deaths of 1,100 women, it is one of the only cancers with a worsening prognosis. French patients currently only have access to two screening techniques. The first, the cervical smear (FCV), is the only one offered to all women even though it often leads to false positives and unnecessary surgeries. The second, the HPV DNA test, is reimbursed only to women for whom unidentified abnormalities are detected after smear (ASC-US). The latest technology, the HPV RNA test, while it offers the most effectiveness in identifying precursors likely to progress to invasive cancers, is not reimbursed in France. However, the HPV RNA test, which is not more expensive than the HPV DNA test, has had its reimbursement blocked since 2016 even though it is already widely covered in other European countries. Women's health should be a priority of the Government. By managing to reduce the proportion of women aged 18 to 24 carrying the viruses responsible for the disease from 23 to 1% in ten years, Australia is proving the effectiveness of a political will which is not limited to vaccination coverage. In the context of the launch of the national organized screening program for cervical cancer, it is feared that the effort to systematize an obsolete test has the opposite effect to that desired. He would therefore like to know whether the Government was considering recommending better screening techniques as part of the national organized screening programme. He questions in particular the possibility of financial coverage by health insurance for the HPV RNA test, in the same way as the HPV DNA test.

Machine translation from French. The official text remains authoritative.

Timeline

No timeline events have been ingested for this record yet.

Votes

No vote records are attached yet.

Versions

No version snapshots stored. Document URLs remain at the source.

Documents

No documents linked.

Sponsors

No sponsors or actors listed by the source.

Related records

No cross-record relationships stored yet.